Leukaemia drug enters phase III studies in MS
September 28, 2007Research and Development
Patients with multiple sclerosis could benefit from a drug currently used to treat leukaemia, with late-stage trials now commencing.Discovered by …
Society launches MS awareness campaign
September 28, 2007Medical Communications
The MS Society has launched a campaign to raise awareness of multiple sclerosis and the help the patient group can …
Regulators and pharma to join forces on drug safety monitoring
September 28, 2007Sales and Marketing reg, safety
Regulators, the pharma industry and academic institutions are to come together in a new global alliance to research drug side-effects. …
mXm launches event ROI Monitor
September 28, 2007Medical Communications
mXm Medical Communications has launched a new tool to measure the return on investment from communications activities at medical meetings.Its …
BMA resists plans for London polyclinics
September 28, 2007Recent government proposals to centralise London healthcare have met resistance among GPs. Independent trade union for doctors, the British Medical …
BMS makes $430m biotech acquisition
September 27, 2007Research and Development
Bristol-Myers Squibb has significantly advanced its strategy to move into biologics with the acquisition of US biotech Adnexus.The $430 million …
News roundup from Datamonitor
September 26, 2007Sales and Marketing
Alnylam and Merck end collaborationBiopharmaceutical company Alnylam Pharmaceuticals and Merck & Co. have mutually agreed to terminate their July 2006 …
UK clinical trials: on the mend?
September 26, 2007Research and Development UK, clinical trials, global, research
How clinical research is organised in the UK is essential to the success of Britain's pharma industry, and to the …
Global products for local people: tailoring your brand strategy
September 25, 2007Medical Communications, Sales and Marketing branding, global
Deciding which aspects of a global brand should be defined centrally and how much freedom there is in any given …
European approval for GSK’s cancer vaccine
September 25, 2007Sales and Marketing
GlaxoSmithKline's cervical cancer vaccine Cervarix has been approved in Europe, setting it up for a head-to-head clash with Sanofi-Pasteur MSD's …
Pfizer’s Celsentri approved in Europe
September 25, 2007Research and Development, Sales and Marketing HIV
Pfizer's Celsentri has been approved in Europe, making it the first in a new, oral class of HIV drugs in …
Brown outlines plans for NHS in a ‘new era’
September 25, 2007The Prime Minister has outlined his plans to provide NHS patients with a more personalised service fit for the 21st …
AstraZeneca denies outsourcing plans
September 25, 2007Manufacturing and Production
AstraZeneca has denied it plans to outsource its drug manufacturing requirements by 2017, following comments made by a senior board …
Takeda claims safety advantages for Actos
September 20, 2007Sales and Marketing
Takeda says new data on its diabetes drug Actos shows a number of safety advantages over GSK's rival product Avandia.Two …
Clinton unveils plans for universal healthcare
September 19, 2007Sales and Marketing
Hilary Clinton has unveiled plans to introduce universal healthcare insurance in America as part of her campaign to become US …
Latest news from Datamonitor
September 17, 2007Research and Development, Sales and Marketing
Cell Therapeutics launches Phase III study for pixantroneCell Therapeutics has launched its phase III clinical trial, known as PIX303, of …
NICE approves MSD and Schering-Plough’s Ezetrol
September 14, 2007Sales and Marketing Inegy, NICE, cv
NICE has approved Merck Sharp & Dohme and Schering-Plough's Ezetrol, but recommended the cheapest version be used – effectively blocking …
Novartis launches Cubicin for MRSA
September 14, 2007Sales and Marketing
Novartis has launched Cubicin – its novel, first-in-class antibiotic – in the UK, in a new indication to treat the …
AstraZeneca looks to outflank cholesterol competitors
September 14, 2007Sales and Marketing
AstraZeneca is to conduct a head-to-head trial of Crestor against rival treatment Vytorin in the hugely competitive cholesterol treatment market.The …
BMS outsources safety monitoring to India
September 14, 2007Sales and Marketing India, safety
A team of 140 people based in Chennai, India, is to help Bristol-Myers Squibb monitor safety and side-effect reports from …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
